| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | JW-55 | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.9 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | Nutlin-3a (-) | GDSC1000 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | PF-562271 | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |